IP Verse

Bristol Myers Squibb Ireland competitive analysis

Latest patents of Bristol Myers Squibb Ireland opposed by its competitors

Explore Bristol Myers Squibb Ireland's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 10, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3246021
Nov 13, 2019Apixaban Formulations12
EP3251660
Oct 16, 2019Apixaban Formulations10
EP3257500
Oct 16, 2019Apixaban Formulations10
EP3017811
Dec 5, 2018Apixaban Formulations9
EP3054926
Jul 25, 2018Hiv Treatment Formulation Of Atazanavir And Cobicistat1
EP2555757
May 25, 2016Atazanavir Sulfate Formulations With Improved Ph Effect1
EP1885339
Jul 29, 2015Formulations Of A Src/Abl Inhibitor3
EP2231639
Apr 1, 2015Crystalline Forms Of N-(Tert-Butoxycarbonyl)-3-Methyl-L-Valyl-(4R)-4-((7-Chloro-4-Methoxy-1-Isoquinolinyl)Oxy)-N-((1R,2S)-1-((Cyclopropylsulfonyl)Carbamoyl)-2-Vinylcyclopropyl)-L-Prolinamide1

Latest PTAB cases involving Bristol Myers Squibb Ireland

Discover the latest PTAB cases involving Bristol Myers Squibb Ireland, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Bristol Myers Squibb Ireland with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BRISTOL MYERS SQUIBB IRELAND UNLIMITED - 42 - -
GENERICS UK319 - - -
INTAS PHARMACEUTICALS2463 -
TEVA PHARMACEUTICAL INDUSTRIES LTD2717 - -